Kiora Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company, which is engaged in developing and commercializing therapies for the treatment of retinal diseases. The Company is engaged in developing KIO-301, a vision-restoring small molecule that acts as a photoswitch specifically created to restore vision in patients with inherited and age-related degenerative retinal diseases, including retinitis pigmentosa (RP). It is also developing KIO-104 for the treatment of retinal inflammatory diseases, including Diabetic Macular Edema (DME) and Posterior Non-Infectious Uveitis, a rare T cell-mediated, intraocular inflammatory disease. KIO-104 is a non-steroidal small-molecule inhibitor of dihydroorotate dehydrogenase (DHODH) formulated for intravitreal delivery and is ideally suited to suppressing overactive T-cell activity to treat the underlying inflammation. KIO-101 focuses on treating the ocular manifestation of patients with autoimmune diseases.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
26-11-13	US$1.230	-7.52%	88,962
26-11-12	US$1.330	-1.48%	20,640
26-11-11	US$1.350	-2.17%	20,536
26-11-10	US$1.380	-8.61%	23,198
26-11-09	US$1.510	+4.86%	41,838

Delayed Quote Nasdaq

More quotes

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

1.230USD

Average target price

12.00USD

Spread / Average Target

+875.61%

Consensus

EPS Estimates

Evolution of Analysts' Estimates - EPS - Kiora Pharmaceuticals, Inc.

Revisions to estimates

Quarterly earnings, Rate of surprise

Rate of surprise - EPS - Quarterly - Kiora Pharmaceuticals, Inc.

Company calendar

Market Closed - Nasdaq 16:00:00 2026-11-13 EST			5-day change	1st Jan Change
1.230 ^USD	-7.52%		-14.58%	-37.56%

11-12	Kiora Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026	CI
09-08	Kiora Pharmaceuticals, Inc. Appoints Keith Lane as Executive Vice President, Head of Clinical Development and Regulatory Affairs, Effective September 1, 2026	CI

Market Cap	7.83M 7.09M 6.56M 5.92M 11.15M 738M 11.55M 78.81M 31.25M 394M 29.37M 28.75M 1.25B	P/E 2026 *	-1.08x	P/E 2027 *	-1.56x
Enterprise Value	7.83M 7.09M 6.56M 5.92M 11.15M 738M 11.55M 78.81M 31.25M 394M 29.37M 28.75M 1.25B	EV / Sales 2026 *	-	EV / Sales 2027 *	-
Free-Float	91.09%	Yield 2026 *	-	Yield 2027 *	-

Markets		Quality
Nasdaq	KPRX	Delayed
CBOE	KPRX	Real-time

11-12	Kiora Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026	CI
09-08	Kiora Pharmaceuticals, Inc. Appoints Keith Lane as Executive Vice President, Head of Clinical Development and Regulatory Affairs, Effective September 1, 2026	CI
08-19	Kiora Pharmaceuticals, Inc. Licenses South Korean Ophthalmic Development And Commercialization Rights For KIO-301 To Chong Kun Dang Pharmaceutical Corporation	CI
08-07	Kiora Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
05-08	Kiora Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-09	Plus Therapeutics, Inc. Appoints Eric J. Daniels as Chief Development Officer, Effective April 20, 2026	CI
04-07	Kiora Pharmaceuticals Inc - Enters securities purchase agreement on April 3, 2026 - SEC filing	RE
04-05	Kiora Pharmaceuticals, Inc. announced that it has received $5.000001 million in funding from ADAR1 Capital Management, LLC and another investor	CI
04-02	Kiora Pharmaceuticals, Inc. announced that it expects to receive $5.000001 million in funding from ADAR1 Capital Management, LLC and another investor	CI
04-02	Kiora Pharmaceuticals, Inc. Announces Resignation of Eric J. Daniels, M.D., MBA as Chief Development Officer, Effective April 17, 2026	CI
03-25	Kiora Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
11-07	Kiora Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
25-10-30	Kiora Pharmaceuticals Joins RARE-X Vision Consortium Promoting Collaboration and Development of New Treatments for Rare Ocular Disorders	CI

Kiora Pharmaceuticals, Inc. Stock

Stocks

KPRX

US49721T5074

Biotechnology & Medical Research

Valuation: Kiora Pharmaceuticals, Inc.

Chart: Kiora Pharmaceuticals, Inc.

Latest news: Kiora Pharmaceuticals, Inc.

Analysts' recommendations: Kiora Pharmaceuticals, Inc.

Press Releases: Kiora Pharmaceuticals, Inc.

News in other languages: Kiora Pharmaceuticals, Inc.

Quotes and Performance

Price Extremes

Managers and Directors: Kiora Pharmaceuticals, Inc.

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Analysts' Consensus

Quarterly earnings, Rate of surprise

24-02-09	HC Wainwright Adjusts Price Target on Kiora Pharmaceuticals to $2 From $3.50, Maintains Buy Rating	MT
23-11-06	HC Wainwright Adjusts Kiora Pharmaceuticals' Price Target to $3.50 From $2, Keeps Buy Rating	MT
23-08-14	HC Wainwright Adjusts Price Target on Kiora Pharmaceuticals to $2 From $7, Keeps Buy Rating	MT
23-05-12	HC Wainwright Raises Kiora Pharmaceuticals' Price Target to $7 From $6, Maintains Buy Rating	MT
23-02-09	Maxim Upgrades Kiora Pharmaceuticals to Buy From Hold, Price Target is $12	MT

11-12	Kiora Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Corporate Update	NE
10-29	Kiora Pharmaceuticals In-Licenses Late-Stage, Oral Neuroprotective Calpain Inhibitor for Central Retinal Artery Occlusion (CRAO) with Planned Expansion into NAION; Asset Completed Phase 3 Clinical Trial in CRAO in Japan	NE
09-08	Kiora Pharmaceuticals Appoints Keith J. Lane as Executive Vice President of Global Clinical Development and Regulatory Affairs	NE
08-19	Kiora Pharmaceuticals Licenses South Korean Ophthalmic Development and Commercialization Rights for KIO-301 to Chong Kun Dang Pharmaceutical Corporation	NE
08-07	Kiora Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update	NE

1 day	-7.52%
1 week	-14.58%
Current month	-21.15%
1 month	-50.20%
3 months	-52.51%
6 months	-54.28%
Current year	-37.56%

1 week	1.2	1.56
1 month	1.2	2.57
Current year	1.2	2.91
1 year	1.2	2.91
3 years	1.2	8.98
5 years	1.2	644.4
10 years	1.2	21,060.02

Manager	Title	Age	Since
Brian Strem CEO	Chief Executive Officer	46	2021-07-25
Melissa Tosca DFI	Director of Finance/CFO	46	2024-06-30
Stefan Sperl COO	Chief Operating Officer	-	-

Director	Title	Age	Since
Praveen Tyle CHM	Chairman	66	2023-09-20
Aron Shapiro BRD	Director/Board Member	48	2021-03-31
Brian Strem BRD	Director/Board Member	46	2021-07-25

Date	Insider	Type	Main position	Quantity	% Market Cap.
9/17/26	Keith Lane	Free	General Counsel	55,000	1.2431%
7/1/26	Melissa Tosca	Tax	Chief Financial Officer	-911	0.0206%
7/1/26	Brian Strem	Tax	Chief Executive Officer	-1,869	0.0422%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
KIORA PHARMACEUTICALS, INC.	-7.52%	-14.58%	-43.96%	-77.50%	7.83M
WUXI APPTEC CO., LTD.	-2.69%	-0.48%	+51.67%	+69.09%	66.33B
ARGENX SE	-0.92%	+7.67%	+14.26%	+90.92%	60.62B
LONZA GROUP AG	0.00%	+0.39%	+20.52%	+98.45%	55.5B
BEONE MEDICINES AG	+0.14%	+2.35%	+13.08%	+109.47%	47.58B
IQVIA HOLDINGS INC.	-2.21%	-2.47%	+18.60%	+36.89%	43.69B
REVOLUTION MEDICINES, INC.	-2.30%	-10.40%	+167.61%	+776.79%	37.27B
CELLTRION, INC.	+2.15%	+1.42%	+15.17%	+56.49%	36.57B
GENMAB A/S	-2.32%	-2.24%	+75.52%	+52.70%	32.22B
INSMED INCORPORATED	+2.62%	+5.90%	-36.55%	+406.95%	26.58B
Average	-1.30%	-1.41%	+29.59%	+162.03%	41B
Weighted average by Cap.	-0.83%	+0.20%	+37.23%	+162.19%

	2026 *	2027 *
Net sales	-	-
Net income	-8.59M -7.78M -7.2M -6.49M -12.24M -810M -12.67M -86.47M -34.29M -433M -32.23M -31.54M -1.37B	-17.53M -15.88M -14.69M -13.26M -24.98M -1.65B -25.86M -176M -69.98M -883M -65.78M -64.39M -2.8B
Net Debt	-	-